Judge Orders ImClone's Scientists Off Patent

Law360 (September 19, 2006, 12:00 AM EDT) -- Scientists at biopharmaceutical company ImClone Systems Inc. copied the work of three Israeli researchers before securing a patent for the firm's top-selling cancer drug, according to a federal judge’s highly anticipated ruling Monday.

The 140-page opinion ordered the U.S. Patent and Trademark Office to strike ImClone’s scientists from the patent for Erbitux, its popular and spendy cancer therapy, and replace them with a trio of inventors from plaintiff Yeda Research and Development Ltd.

The order was penned by Judge Naomi R. Buchwald in the U.S. District...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.